Your browser is no longer supported. Please, upgrade your browser.
Codiak BioSciences, Inc.
Index- P/E- EPS (ttm)-0.98 Insider Own2.40% Shs Outstand23.52M Perf Week-1.55%
Market Cap432.53M Forward P/E- EPS next Y-4.52 Insider Trans0.85% Shs Float19.20M Perf Month-26.79%
Income-95.40M PEG- EPS next Q-1.54 Inst Own63.80% Short Float1.93% Perf Quarter104.33%
Sales1.40M P/S308.95 EPS this Y-75.00% Inst Trans- Short Ratio1.79 Perf Half Y-
Book/sh- P/B- EPS next Y75.70% ROA- Target Price- Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range7.90 - 37.85 Perf YTD-43.07%
Dividend- P/FCF- EPS past 5Y- ROI43.80% 52W High-51.41% Beta-
Dividend %- Quick Ratio1.50 Sales past 5Y- Gross Margin- 52W Low132.78% ATR2.44
Employees101 Current Ratio1.50 Sales Q/Q900.00% Oper. Margin- RSI (14)38.65 Volatility11.07% 11.02%
OptionableNo Debt/Eq- EPS Q/Q8.70% Profit Margin- Rel Volume0.54 Prev Close18.39
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume206.77K Price18.39
Recom1.50 SMA20-16.12% SMA50-23.78% SMA2001.75% Volume0 Change0.00%
Nov-09-20Initiated Wedbush Outperform $19
Nov-09-20Initiated Goldman Buy $29
Feb-20-21 01:27AM  
Feb-17-21 04:30PM  
Feb-11-21 10:18PM  
Feb-09-21 04:17PM  
Feb-04-21 07:30AM  
Jan-21-21 09:00AM  
Jan-13-21 11:58PM  
Dec-30-20 07:00AM  
Dec-21-20 09:00AM  
Nov-27-20 11:55AM  
Nov-23-20 07:30AM  
Nov-19-20 04:05PM  
Nov-09-20 08:00AM  
Oct-23-20 06:00PM  
Oct-13-20 07:04PM  
Codiak BioSciences, Inc. is harnessing exosomesAnatural intercellular messengersAto pioneer a new class of biologic medicines, exosome therapeutics. It develops the engEx Platform, versatile exosome engineering and manufacturing platform, to expand upon the innate properties of exosomes to design novel exosome therapeutics. The company's two lead engEx product candidates, exoSTING and exoIL-12. Its engEx Platform has the potential to produce a broad pipeline of product candidates for the treatment of diseases with high unmet medical need, including in the areas of oncology, immune-based diseases, metabolic and fibrotic disorders, neurodegenerative disorders, and rare diseases. Codiak BioSciences, Inc. has a strategic collaboration with the Ragon Institute of MGH, MIT and Harvard to investigate the potential of exoVACC vaccine platform for SARS-CoV-2 and human immunodeficiency virus. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Morrison BriggsDirectorFeb 17Buy21.004,76199,9814,761Feb 17 06:05 PM